Grail

Grail CROIC

The Cash Return on Invested Capital (CROIC) of Grail (GRAL) as of Nov 2, 2026 is -11.58 %. In the previous year, Cash Return on Invested Capital (CROIC) was -23.26 % — a change of -50.21% (higher).

CROIC

-11.58 %

YoY

-50.21%

Last updated:

Cash Return on Invested Capital (CROIC) of Grail is 2025 -11.58 % . Cash Return on Invested Capital (CROIC) of Grail was 2024 -23.26 % . It decreases by -50.21% higher compared to the previous year.

The Grail CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-37.41 USD
Jan 1, 2019
-45.25 USD
Jan 1, 2020
-43.00 USD
Jan 1, 2021
-8.03 USD
Jan 1, 2022
-12.54 USD
Jan 1, 2023
-16.69 USD
Jan 1, 2024
-23.26 USD
Jan 1, 2025
-11.58 USD
The Grail CROIC history
YEARCROICYoY
-11.58 %-50.21%
-23.26 %+39.35%
-16.69 %+33.15%
-12.54 %+56.20%
-8.03 %-81.33%
-43.00 %-4.99%
-45.25 %+20.96%
-37.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Grail Stock analysis

What does Grail do? Grail Inc generates revenue through its Galleri and Beyond products, which are designed for multi-cancer early detection. Galleri is a commercially available screening test that identifies multiple cancer types in early stages using methylation-based technology, supporting healthcare providers in guiding diagnostic pathways. The company targets healthcare systems, hospitals, and insurance providers as key buyers, focusing on population-scale clinical studies and precision oncology applications. Its platform integrates next-generation sequencing, machine learning, and automation to address cancer detection across various care continuum segments. The business model centers on selling Galleri tests to healthcare institutions for use in patient screening programs, with Beyond serving as an additional product for precision oncology needs. Buyers include healthcare systems seeking to implement early cancer detection protocols and insurance companies aiming to reduce long-term treatment costs through early intervention. The company leverages its methylation-based platform to provide solutions for risk stratification, minimal residual disease detection, and treatment monitoring, aligning with the growing demand for advanced cancer screening technologies. Grail Inc's revenue streams are derived from the commercialization of Galleri, which is positioned as a multi-cancer early detection (MCED) tool, and Beyond, which supports specialized oncology applications. The company's target segments encompass healthcare providers, insurance partners, and research institutions involved in population-scale studies. By focusing on early detection and precision oncology, Grail Inc addresses unmet needs in cancer care through its technology-driven approach. Grail is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Grail stock

Cash Return on Invested Capital (CROIC) of Grail is -11.58 % in 2025.

Cash Return on Invested Capital (CROIC) of Grail changed from -23.26 % to -11.58 %, representing a -50.21% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Grail since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Grail with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Grail

All Key Metrics — Grail